CPIX Explodes Higher but 3.60 Now Decides the Next Big MoveHello, traders! CPIX has shifted abruptly from a quiet 4-hour consolidation into a high-volatility bullish phase after clearing the key $3.60 ceiling and closing near $4.26, with the latest expansion briefly stretching as high as $6.20. That breakout matters because it ends the prior neutral-to-bearish structure and replaces it with a clear momentum-led regime. At the same time, the long upper wick shows the market already met heavy supply into the spike, so the move is strong, but not clean. This now looks less like a straight-line continuation and more like a breakout that needs to prove itself through acceptance above the former range high.
From a near-term technical perspective, $3.60 is the level that matters most. It was the multi-week cap, it has now flipped into first support, and it is the most logical throwback area if price cools further. As long as CPIX holds that zone on a 4-hour closing basis, the primary path still favors bullish continuation, first into the $4.50โ$5.00 area and then toward $5.50, with a possible retest of the spike zone near $5.80 to $6.00 if momentum rebuilds. The alternative path is straightforward: if price loses acceptance and starts closing back under $3.80, the breakout begins to look unstable, and a deeper retracement toward $3.46, $3.25, or even $3.20 comes into play.
The broader structure still leans constructive, but it is clearly overextended. Price is trading well above the MA20 at $3.25, MA60 at $3.15, and MA120 at $3.46, while MACD remains firmly bullish and SuperTrend still points LONG with support around $3.48. Even so, the widening gap from the moving averages and the ATR spike to 0.348 warn that mean reversion risk is now part of the setup. That keeps the preferred stance bullish but selective: strength above $4.50 would reopen the path toward the highs, while a failed hold above the breakout zone would shift the focus from momentum continuation to volatility compression and deeper reset. For now, CPIX remains bullish above $3.60, but that level is the line separating continuation from a failed breakout.
Cumberland Pharmaceuticals Inc.
No trades
No trades
In-depth trading ideas
๏ปฟTriple Top on Cumberland Pharmaceuticals. CPIXPlus a reversal signal on the 1.618 vWAP Fibonacci cloud exit. Its a risky reversal take, so a stop loss goes right where the cloud starts up again. We can enter the cloud, but cannot exit in it without calling quits. None of the lagging indicators have fired off yet, which is common on pivot/reversal takes.
CPIX โ 30-Min Long Trade Setup!๐
๐น Asset: Cumberland Pharmaceuticals Inc. (CPIX)
๐น Timeframe: 30-Min Chart
๐น Setup Type: Descending Triangle Breakout Long Trade
๐ Trade Plan (Long Position)
โ
Entry Zone: Above $5.36 (Breakout Confirmation)
โ
Stop-Loss (SL): Below $4.74 (Break of Support & Trendline)
๐ฏ Take Profit Targets
๐ TP1: $6.13 (First Resistance Level)
๐ TP2: $7.23 (Final Target โ Extended Bullish Move)
๐ Risk-Reward Ratio Calculation
๐ Risk (SL Distance): $5.36 - $4.74 = $0.62 risk per share
๐ Reward to TP1: $6.13 - $5.36 = $0.77 (1.24 R/R)
๐ Reward to TP2: $7.23 - $5.36 = $1.87 (3.02 R/R)
๐ Technical Analysis & Strategy
๐ Descending Triangle Breakout Setup: CPIX has been consolidating in a downward-sloping triangle, with a breakout expected at $5.36.
๐ Trendline & Support Bounce: The price is attempting to break out of the pattern, indicating buyer accumulation.
๐ Breakout Confirmation: A strong bullish candle above $5.36 with increasing volume would confirm momentum.
๐ Momentum Shift Expected: If price holds above $5.36, a rally toward $6.13 (TP1) and $7.23 (TP2) is likely.
๐ Key Support & Resistance Levels
๐ข $4.74 โ Strong Support / Stop-Loss Level
๐ก $5.36 โ Entry / Breakout Level
๐ด $6.13 โ First Resistance / TP1
๐ข $7.23 โ Final Target / TP2
๐ Trade Execution & Risk Management
๐ Volume Confirmation: Ensure strong buying volume above $5.36 before entering.
๐ Trailing Stop Strategy: Move SL to entry ($5.36) after TP1 ($6.13) is hit.
๐ฐ Partial Profit Booking Strategy:
โ Take 50% profits at $6.13, let the rest run to $7.23.
โ Adjust Stop-Loss to Break-even ($5.36) after TP1 is reached.
โ ๏ธ Fake Breakout Risk
โ If price fails to hold above $5.36 and breaks back down, it could indicate a false breakoutโexit early.
โ Wait for a strong candle close above $5.36 for confirmation before entering aggressively.
๐ Final Thoughts
โ Bullish Setup โ Holding above $5.36 could lead to higher targets.
โ Momentum Shift Possible โ Watch for volume confirmation.
โ Favorable Risk-Reward Ratio โ 1:1.24 to TP1, 1:3.02 to TP2.
๐ก Stick to the plan, manage risk, and trade smart! ๐๐
๐ #StockTrading #CPIX #CumberlandPharmaceuticals #BreakoutTrade #TechnicalAnalysis #MarketTrends #ProfittoPath #DayTrading #MomentumStocks #SwingTrading #TradingView #LongTrade #TradeSmart #RiskManagement #StockBreakout #Investing #StockAlerts #ChartAnalysis ๐๐
$CPIXCumberland Pharmaceuticals shares are trading higher after the company announced the FDA approved expanded labeling for Caldolor to now include use in pre-operative administration.
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and rheumatology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ injection, for the treatment of certain serious bacterial infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. The company markets and sells its products through sales representatives and district managers. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.





